Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 1/20 | 0.31 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | SKP1 | P63208 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21381973 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2JAK2MITFMTNR1A | |
| SCHEMBL23150450 | 1.00 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2JAK2MITFMTNR1A | |
| SCHEMBL6022110 | 0.88 | ALDH1A1 (0.34) | ALDH1A1SMN1; SMN2JAK2MITFMTNR1A | |
| SCHEMBL1837664 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2JAK2MITFMTNR1AMTNR1B | |
| SCHEMBL29068374 | 0.79 | EPHX1 (0.44) | ALDH1A1 | |
| SCHEMBL23150504 | 0.79 | EPHX1 (0.44) | ALDH1A1 | |
| SCHEMBL23150505 | 0.79 | EPHX1 (0.44) | ALDH1A1 | |
| SCHEMBL23150503 | 0.79 | EPHX1 (0.44) | ALDH1A1 | |
| SCHEMBL18605463 | 0.79 | CKS1B (0.40) | ALDH1A1MTNR1AMTNR1BCKS1BSKP1 | |
| SCHEMBL18605462 | 0.79 | CKS1B (0.40) | ALDH1A1MTNR1AMTNR1BCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210094972-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094972-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP1A1 | ALDH1A1 103/4885SMN1; SMN2 2734/4885JAK2 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.